Nattokinase for Venous Return
Nattokinase has fibrinolytic activity with no venous insufficiency outcome data.
Overview
Verdict
How It Works
Dosing & Protocol
Typical dose
- Recommended dose
- 2000 FU/day
- Expected timeframe
- 4-8 weeks
Protocol
- form
- Not applicable
- duration
- Not applicable
- co factor
- Evidence is insufficient. Venous return is determined by blood volume, venous tone, the skeletal muscle pump, respiratory pump, valve competence and right atrial pressure - none of which nattokinase has been shown to affect. Its documented activity is fibrinolytic: degrading fibrin and modulating plasminogen activator inhibitor-1. Small trials have measured blood pressure, fibrinogen and clotting factors, and one small study examined leg oedema during prolonged sitting, but no randomised trial has measured venous return, venous tone or venous insufficiency outcomes. The idea seems to originate from conflating thrombosis prevention with venous function, which are separate problems - and even for thrombosis, no clinical endpoint trial exists.
- titration
- Not applicable
- starting dose
- Not established for this outcome
Evidence
What the studies say
No studies are yet linked to both Nattokinase and Venous Return.
Safety
Caveats
Bleeding risk, particularly with anticoagulants. Avoid before surgery.
Less likely to help if
Medical Disclaimer
The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.
Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.